XML 133 R112.htm IDEA: XBRL DOCUMENT v3.20.4

Contingencies and commitments (KYPROLIS ANDA Patent Litigation) (Details) - patent		19 Months Ended
	May 08, 2020	Apr. 30, 2018
Gain Contingencies [Line Items]
Number of asserted patents	3
Onyx Therapeutics, Inc [Member] | KYPROLIS (carfilzomib) Patent Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed		1

X

- Definition

Number Of Asserted Patents

+ References

No definition available.

+ Details

Name:	amgn_NumberOfAssertedPatents
Namespace Prefix:	amgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of entity's patents that another entity has allegedly infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=amgn_KYPROLIScarfilzomibPatentLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: